• From ALOX5 Biology to Defensible Protein Evidence

  2026-09-28

  Huang et al. connect ALOX5, ferroptosis, and epithelial barrier dysfunction in CRSwNP. This thought-leadership guide translates those findings into a rigorous Western blot strategy using ultrasensitive chemiluminescent detection without overstating causality or clinical readiness.

• Baicalein and the Assay Logic of Selective Protection

  2026-09-28

  Baicalein (5,6,7-trihydroxy-2-phenylchromen-4-one) is a useful probe of 12-lipoxygenase biology, but its value depends on separating pathway engagement from cellular outcomes. This article connects recent chemotherapy-neurotoxicity research to a rigorous framework for interpreting cancer, apoptosis, and inflammation assays—without conflating distinct compounds or mechanisms.

• FAISL Stabilizes FAK to Drive TNBC Metastasis

  2026-09-27

  A 2024 study identifies the lncRNA FAISL as a stabilizer of focal adhesion kinase (FAK), showing that it limits calpain-2-mediated FAK proteolysis and supports triple-negative breast cancer progression. The findings connect RNA–protein interactions with focal-adhesion turnover and suggest that targeting FAISL is distinct from broadly inhibiting cysteine proteases.

• SARS-CoV-2 PLpro Rewires ER Protein Stability

  2026-09-26

  This study shows that ER-anchored SARS-CoV-2 Nsp3 papain-like protease can both deubiquitinate ER-associated degradation substrates and cleave ER-resident proteins. Its distinct effects on INSIG-1, SREBP-1, and SREBP-2 reveal that PLpro may regulate host protein abundance through more than one catalytic route, with implications for interpreting viral protein–host interactions.

• MLN2238: Proteasome β5 Subunit Inhibitor

  2026-09-25

  Use MLN2238 to connect proteasome β5 target engagement with stress signaling, apoptosis, and resistance phenotypes in oncology models. A practical workflow pairs a concentration-and-time pilot with orthogonal proteasome, ROS/JNK/CREB, and cell-fate readouts—while keeping the paper’s fly findings distinct from proposed cell-culture conditions.

• Firefly Luciferase mRNA for Delivery Assays

  2026-09-25

  Use a bright, directly translated reporter to compare mRNA delivery, cytoplasmic translation, and formulation performance without relying on plasmid transcription. This practical guide pairs the Cap1-capped, 5-moUTP-modified transcript with a lipoplex workflow and controls that help distinguish weak delivery from cell-health or assay-readout problems.

• CAPE as a Probe of NF-κB in Neurodegeneration

  2026-09-24

  A translational framework for using CAPE to test NF-κB contributions to Fyn-driven neuroinflammation—while separating pathway evidence from model-specific and cross-domain claims.

• 2-NBDG Glucose Uptake Assay Kit in HCC Research

  2026-09-24

  Add a rapid, non-radioactive glucose-uptake readout to hepatocellular carcinoma studies of sorafenib response. The 2-NBDG Glucose Uptake Assay Kit complements lipid-metabolism and ferroptosis measurements, while keeping glucose transport distinct from the mechanisms those assays test.

• Oleic Acid and the Logic of Lipid Injury Models

  2026-09-23

  Oleic Acid (C18:1(9Z)) can do more than raise cellular lipid burden: used thoughtfully, it helps translational researchers probe how lipid context shapes hepatocyte injury, inflammation, and pathway-specific rescue. This article connects recent hepatic ischemia-reperfusion findings to practical assay design, controls, and the limits of translation.

• Bradykinin BA5201: Practical Vascular Assay Guide

  2026-09-23

  Bradykinin (BA5201) provides a defined peptide stimulus for controlled vascular, permeability, smooth muscle, pain, and inflammation research workflows. It should be handled as a research reagent with prompt use of prepared solutions, and it is not intended for diagnostic, therapeutic, or medical use.

• Cy7 NHS Ester: Practical Labeling and QC Guide

  2026-09-22

  Cy7 NHS ester (A8109) is a water-soluble amino-group labeling reagent for preparing near-infrared fluorescent conjugates of proteins, peptides, and other biomolecules. It is suited to controlled in vitro and imaging workflows, but solutions should be used promptly and the reagent should not be treated as validated for quantitative biodistribution, clinical use, or any application without matrix-specific QC.

• Protease Inhibitor Cocktail: From Lysate to Insight

  2026-09-22

  Protease Inhibitor Cocktail K1019 protects labile proteins while connecting sample-handling decisions to mechanistic cancer research. Learn how its DMSO and EDTA format supports Western blotting, co-immunoprecipitation, and TP53-centered assays without obscuring downstream interpretation.

• Gap26: Connexin 43 Mimetic Peptide Workflows

  2026-09-21

  Gap26 provides an acute pharmacological way to test how connexin 43-dependent communication shapes calcium waves, ATP release, and epithelial–stromal signaling. This workflow translates mitochondrial-transfer findings from an asthma model into practical experiments while clearly separating validated product conditions from hypothesis-generating applications.

• Isradipine (Dynacirc): Reading Calcium Biology

  2026-09-21

  A translational framework for using Isradipine (Dynacirc) as an L-type calcium-channel probe across vascular, neuronal, and neurodegenerative disease models while avoiding overinterpretation of pharmacological selectivity.

• Porcupine Inhibition in Severe Sclerosteosis

  2026-09-20

  A 2025 Bone Research study evaluates LGK974-mediated PORCN inhibition as a pharmacological strategy for SOST-deficient sclerosteosis. Combined osteoblast, osteoclast, mouse, and mechanoadaptation experiments indicate reduced pathological bone formation, while sex-dependent Axin2 responses highlight important translational questions.

8088 records 1/540 page Next 12345 下5页 Last page